🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Jazz Pharmaceuticals plc JAZZ R3KPHARMA

Healthcare · Biotechnology · Ireland
https://www.jazzpharma.com
Company Profile ↓
$240.07
+104.98% 1Y
Mkt Cap$15.58B
P/E16.44
P/B3.25
52W High$261.62
52W Low$116.67
Book Value$74.10
EPS (TTM)$14.60

Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 22.1%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 24.5% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 16.4, below the sector median of 24.8.

Healthy Margins

Maintains a net profit margin of 20.4%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $4.27B (+4.9% YoY); net profit $-356.15M.
  • Trailing 12 Months Year-on-year growth — revenue +15.5%, earnings -163.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 24.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:24.48%
1 Year:15.50%

Compounded Profit Growth

5 Years:-
1 Year:-163.58%

Stock Price Performance

1 Year:+104.98%
6 Months:+29.49%
3 Months:+3.46%
1 Month:-6.43%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 85% of range
$116.67 $261.62
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)41.51 · Neutral
Price Performance
1M-6.43%
3M+3.46%
6M+29.49%
1Y+104.98%
Valuation vs Sector

P/E of 16.44 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 22.1%.
  • Excellent profit margin of 20.4%.
  • Compounding revenue at 24.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
16.44
Industry PE
24.83
Forward P/E
9.31
PEG Ratio
0.96
Book Value
$74.10
Price to Book
3.25
P/S
3.40
EV/EBITDA
9.36
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
24.48%
Profit 5Y
-
Revenue (YoY)
15.50%
Earnings (YoY)
-163.58%

Profitability & Returns

ROCE
-4.57%
ROE
22.11%
ROA
6.86%
Profit Margin
20.45%
Op Margin
26.91%
Gross Margin
91.35%
EPS (Latest Qtr)
$2.78
EPS (TTM)
$14.60

Balance Sheet & Liquidity

Debt/Equity
0.92
Quick Ratio
1.38
Current Ratio
1.78
Debt
$4.41B
Total Assets
$11.08B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.92%
Chg in Prom Hold
-0.07%
FII / Inst Holding
102.78%
Chg in FII Hold
-0.28%

Financial Snapshot

Enterprise Value
$15.58B
Total Revenue (TTM)
$4.60B
EBITDA
$1.93B
Free Cash Flow
$1.43B
Operating Cash Flow
$1.66B
Shares Outstanding
64.91M
Gross Margin
91.35%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JAZZ Jazz Pharmaceuticals plc R3KPHARMA 240.07 16.44 $15.58B 0.00% -4.57% 22.11% 24.48% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----376.05M394.39M411.86M-444.61M500.48M469.37M476.46M508.19M534.13M537.70M581.74M534.73M562.44M600.89M665.52M607.58M751.81M838.12M813.72M932.88M940.65M892.81M957.32M972.14M901.98M1.02B1.05B-897.80M1.05B1.13B1.20B1.07B1.21B
Cost of Revenue ----------------------------------104.60M116.27M128.88M153.53M134.10M-
Gross Profit 314.89M310.48M355.13M347.31M358.96M348.61M360.98M376.77M404.85M406.93M461.38M438.62M441.00M469.82M495.75M500.92M541.18M501.55M530.20M554.85M611.15M-------------793.20M929.44M997.23M1.04B934.80M-
Operating Expenses ----------------------------------849.10M710.47M897.22M789.86M598.20M-
Operating Income -121.16M168.74M136.25M-136.14M165.04M86.45M-87.81M153.20M188.78M-133.74M204.28M133.10M--189.67M198.13M196.21M-162.12M-69.59M28.37M87.55M85.55M24.76M126.06M157.64M172.39M66.21M199.44M260.21M--55.90M218.97M100.01M254.53M336.60M248.20M
EBITDA ----------------------------------108.70M-514.11M235.86M433.05M520.50M-
Interest Expense ----------------------------------53.70M47.36M48.58M45.41M39.90M-
Pretax Income -----------------------------------109.80M-735.55M9.04M208.47M299.20M-
Tax Provision -----------------------------------17.80M-17.17M-242.42M4.96M6.10M-
Net Income 82.76M75.81M114.50M89.83M116.69M86.51M105.60M63.53M232.21M45.99M92.32M149.32M159.47M85.20M261.90M102.28M73.99M-157.83M114.80M148.23M133.41M121.83M-363.32M-52.83M1.65M34.66M-19.65M69.42M104.44M146.82M-14.62M168.57M215.06M--92.50M-718.47M251.41M203.45M293.10M192.80M
Diluted EPS 1.321.211.851.451.911.411.721.033.790.751.502.412.641.474.561.781.29-2.822.062.642.332.09-6.11-0.860.030.55-0.311.041.522.14-0.232.493.42--1.52-11.744.083.214.432.78
R&D Expense -31.25M39.09M47.80M-44.93M40.16M47.36M-62.67M56.13M51.16M-60.10M62.38M79.86M------------------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 128.45M173.78M272.28M585.98M872.42M1.17B1.32B1.49B1.62B1.89B2.16B2.36B3.09B3.66B3.83B4.07B4.27B
Operating Income 15.93M57.79M127.83M197.84M340.31M195.59M508.22M591.65M528.84M614.84M532.37M378.07M170.28M-65.53M578.58M716.63M-430.24M
Net Income -6.84M32.78M124.98M288.59M216.31M58.39M329.54M396.83M487.85M447.10M523.37M238.62M-329.67M-224.06M414.83M560.12M-356.15M
Diluted EPS -0.230.832.674.793.510.935.236.417.967.309.094.22-5.52-3.586.108.65-5.84
R&D Expense 36.56M25.61M14.12M20.48M41.63M85.18M135.25M162.30M198.44M226.62M299.73M------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --135.73M253.57M1.97B2.24B3.34B3.33B4.80B5.12B5.20B5.54B6.54B12.30B10.84B11.39B12.01B11.66B
Total Equity -92.88M-72.83M30.55M192.79M1.12B1.30B1.37B1.60B1.88B2.71B2.76B3.11B3.66B3.97B3.09B3.74B4.09B4.32B
Cash & Equivalents 24.90M15.60M44.79M82.08M387.20M636.50M684.04M988.78M365.96M386.04M309.62M637.34M1.06B591.45M881.48M1.51B2.41B1.39B
Long Term Debt ---0427.07M544.40M1.33B1.15B1.99B1.54B1.56B1.57B1.85B6.02B5.69B5.11B6.08B4.33B
Current Liabilities --59.94M52.87M191.54M204.03M216.80M226.64M257.41M293.95M345.49M364.49M653.75M809.30M933.19M1.54B1.04B2.24B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -15.88M58.87M151.60M249.75M288.43M407.61M531.94M592.39M693.09M798.90M776.40M899.65M778.51M1.27B1.09B1.40B1.36B
Investing Cash Flow -6.12M-2.14M-81.23M-395.29M-16.26M-1.07B-2.25M-1.75B-268.95M-394.49M-155.30M-1.01B-5.21B-446.23M-163.06M-508.19M-1.51B
Financing Cash Flow 12.69M-27.53M-33.08M448.53M-23.86M711.03M-214.32M540.99M-409.11M-479.13M-293.75M528.07M3.97B-529.49M-305.25M20.52M-873.38M
Capital Expenditure ----------20.37M-40.13M-15.00M-27.64M-29.05M-23.96M-38.07M-58.75M
Free Cash Flow ---------778.53M736.27M884.64M750.87M1.24B1.07B1.36B1.30B
Share Buybacks --00136.48M42.22M61.55M278.30M98.80M523.67M301.45M146.54M054.00K269.76M311.43M125.02M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------------
Operating Margin % 12.4%33.3%46.9%33.8%39.0%16.7%38.4%39.8%32.7%32.5%24.6%16.0%5.5%-1.8%15.1%17.6%-10.1%
Net Margin % -5.3%18.9%45.9%49.2%24.8%5.0%24.9%26.7%30.1%23.6%24.2%10.1%-10.7%-6.1%10.8%13.8%-8.3%
ROE % 9.4%107.3%64.8%25.7%16.7%4.3%20.6%21.1%18.0%16.2%16.8%6.5%-8.3%-7.3%11.1%13.7%-8.2%
ROCE % -76.2%63.7%11.1%16.7%6.3%16.4%13.0%10.9%12.7%10.3%6.4%1.5%-0.7%5.9%6.5%-4.6%

Shareholding Pattern

Insiders
2.92%
Institutions
102.78%
Public Float
105.88%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.19% 5.97M $1.44B
2 FMR, LLC 7.10% 4.61M $1.11B
3 Vanguard Portfolio Management LLC 4.68% 3.04M $730.94M
4 Vanguard Capital Management LLC 4.20% 2.73M $657.14M
5 Capital World Investors 4.16% 2.70M $649.42M
6 LSV Asset Management 3.50% 2.28M $547.72M
7 Franklin Resources, Inc. 3.14% 2.04M $491.17M
8 State Street Corporation 3.08% 2.00M $481.44M
9 Dimensional Fund Advisors LP 2.64% 1.71M $412.53M
10 Fuller & Thaler Asset Management Inc. 2.52% 1.64M $394.46M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JAZZ

Yahoo Finance Fri, 04 Sep 2026

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. J…

Yahoo Finance Wed, 02 Sep 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:

Yahoo Finance ue, 01 Sep 2026

Duncan Ferguson Joins Neovii Pharmaceuticals AG to Lead Global Commercial Expansion as Chief Commercial Officer

RAPPERSWIL, SWITZERLAND - September 1, 2026 (NEWMEDIAWIRE) - Neovii Pharmaceuticals AG today announced the appointment of Duncan Ferguson as Chief Commercial Officer (CCO), effective 1 September 2026. Ferguson joins the company at a pivotal…

Yahoo Finance ue, 01 Sep 2026

Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere

Check out the companies making headlines yesterday:

Yahoo Finance Mon, 31 Aug 2026

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase 3 HERIZON-GEA-01 trial results showing that Ziihera combined with chemotherapy achieved a statist…

Yahoo Finance Mon, 31 Aug 2026

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated stati…

JAZZ — Frequently Asked Questions

What is the current share price of Jazz Pharmaceuticals plc (JAZZ)?

As of 2026-09-19 21:16 PDT, Jazz Pharmaceuticals plc (JAZZ) trades at $240.07 on NasdaqGS. Its 52-week range is $116.67 to $261.62.

What is the market capitalisation of JAZZ?

Jazz Pharmaceuticals plc (JAZZ) has a market capitalisation of $15.58B on NasdaqGS.

What is the P/E ratio of JAZZ?

JAZZ trades at a trailing price-to-earnings (P/E) ratio of 16.44. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.25.

What is the return on equity (ROE) of JAZZ?

JAZZ has a return on equity (ROE) of 22.11%. Its return on capital employed (ROCE) is -4.57%.

Is JAZZ a good stock to buy?

This page provides a data-driven analysis of Jazz Pharmaceuticals plc (JAZZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space